The Potential of Exosomes

December 22, 2021

이 페이지 공유

It was not long ago when exosomes were thought to merely be waste products excreted by cells. They had no apparent importance or obvious special quality. Current research has discovered that these nanoparticles are a perfect representative of their cell of origin, facilitating gene transfer between cells. Simply put, they have the ability to act on behalf of a parent cell across the body, which with development could open the door to their use in targeted therapeutic drug delivery. Worth noting too is that exosomes are smaller and less complex than their host cells. These attributes give the biotech industry a glimpse at, and hope in, their currently untapped potential. As research and discovery of their biological nature begins to unfold, it is exciting to hear the potential of exosomes linked to early diagnosis of cancers. In exosomes, are we looking at the next modality for cell therapies?

 

What are Exosomes?

 

So, what are they? An exosome is a small endosomal derived extracellular vesicle that is 30-150 nanometers (nm) in diameter. In mammals, exosomes are derived from a variety of sources including stem cells, body fluids (blood, milk, saliva, cerebral spinal fluid, lymph, etc.) and dendritic cells. Although not fully understood, exosomes have an important role in physiological and pathological processes because of their ability to mediate intracellular and extracellular communication. Exosomes are capable of carrying lipids, proteins, and RNAs.

 

Their ability to communicate and carry biologically active cargo makes them a versatile cell free option for therapeutics. As such, they could be used in therapeutics for wound healing, cancer, and myocardial ischemia. Exosomes can also cross the blood brain barrier and could be used in therapeutics against Alzheimer’s, Parkinson’s, and traumatic brain injuries. Because of their non-immunogenic nature, exosomes are also well positioned to be drug delivery carriers. Exosome expression has been observed in pathological cells such as cancer and HIV revealing that they also have the potential to be used as a diagnostic tool for early detection of a diseased state.

 

Current Market Landscape

 

At the time of writing there are 192 clinical trials based on exosomes1. However, there are currently no exosome-based therapeutics that have been approved by the Food and Drug Administration. Current advancement in understanding the mechanism of action of exosomes has led to several industries surrounding this emerging field. The exosome industry has a compound annual growth rate of 37.8% with a potential to be valued at $368 million dollars by 20222.

 

There are several collaborations for the development and commercialization of exosomes. Codiak Biosciences and Jazz Pharmaceutical Inc. collaborated in order to understand the solid tumors and hematological malignancies. Avalon GloboCare Corp formed a collaboration with Weill Cornell Medicine to form cGMP-grade standards for exosomes derived from human endothelial cells. In addition to those companies, several others such as Capricor Therapeutics Inc, Boehringer Ingelheim* GmbH, United Therapeutics Corporation, and Lonza, are involved with the research, development, and manufacturing of exosomes3. On the manufacturing front, Lonza recently announced the acquisition of Codiak’s manufacturing facility and licensed its exosome manufacturing technology4. It is clear from this investment of time, money, and resource that the biopharmaceutical industry wholeheartedly believes in their potential.

 

The Future of Exosomes

 

So, could exosomes be the next level of cell therapy? We cannot predict the future. What we can do is innovatively and scientifically follow the biological trail set before us, allowing the full nature of exosomes to be discovered. And their potential? Maybe it is as big as we want to make it.

 

To learn more about exosomes, and how to overcome any potential challenges in producing exosomes you can watch our on-demand webinar.

 

References

 

 

Follow us on social media now to get access to the latest news, updates and events

Juliet Kallon, Bioprocess Specialist, Scientific and Laboratory Services

Juliet Kallon is a Bioprocess Specialist for the South East Region of the US and has been with us since 2018. She has many years of experience in the biopharmaceutical industry. Her work experience includes primary focus on the downstream purification and analysis of monoclonal antibodies and recombinant proteins at the process development and pilot scale level. Juliet’s area of expertise is in the development and scale-up of plasmid DNA processes from benchtop to manufacturing scale.
Juliet Kallon is a Bioprocess Specialist for the South East Region of the US and has been with us since 2018. She has many years of experience in the biopharmaceutical industry. Her work experience includes primary focus on the downstream purification and analysis of monoclonal antibodies and recombinant proteins at the process development and pilot scale level. Juliet’s area of expertise is in the development and scale-up of plasmid DNA processes from benchtop to manufacturing scale.
더 읽어보기

Morenje Mlawa, Bioprocess Specialist, Scientific and Laboratory Services

Morenje is a Bioprocess Specialist for Maryland, District of Columbia, and Virginia (Mid-Atlantic, USA). His tenure with us began in 2018. He has many years of industry experience in process development (both upstream and downstream), technology transfer, technology development, and regulatory cell banking and testing. His expertise ranges from small-scale to manufacturing-scale.
Morenje is a Bioprocess Specialist for Maryland, District of Columbia, and Virginia (Mid-Atlantic, USA). His tenure with us began in 2018. He has many years of industry experience in process development (both upstream and downstream), technology transfer, technology development, and regulatory cell banking and testing. His expertise ranges from small-scale to manufacturing-scale.
더 읽어보기

Nebiyat Tsegaye, Bioprocess Specialist, Scientific and Laboratory Services

Nebiyat joined the team in 2020 as a Bioprocess Specialist supporting the Mid-Atlantic region. She has many years of cross-functional biopharmaceutical industry experiences in upstream and downstream technologies, CMC, and technology transfer to CMOs and internal manufacturing. Prior to joining us, she worked in cell culture process development with a focus on monoclonal antibodies and gene therapy processes (adherent and suspension) from benchtop up to 200 liter bioreactors.
Nebiyat joined the team in 2020 as a Bioprocess Specialist supporting the Mid-Atlantic region. She has many years of cross-functional biopharmaceutical industry experiences in upstream and downstream technologies, CMC, and technology transfer to CMOs and internal manufacturing. Prior to joining us, she worked in cell culture process development with a focus on monoclonal antibodies and gene therapy processes (adherent and suspension) from benchtop up to 200 liter bioreactors.
더 읽어보기
  • Category
  • Author
  • Sort By
Results